-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors show high response rates and lasting clinical benefits in microsatellite instability-high/mismatch repair defect (MSI-H/dMMR) tumors
.
However, about 50%-60% of tumor patients do not respond to a single dose of anti-PD-1/PD-L1 antibody, and about 50% of responders will relapse within 6-12 months
immunity
This is a phase Ib clinical trial aimed at evaluating the anti-PD-L1 antibody LY3300054 single agent or the combined anti-TIM-3 antibody LY3321367 in patients with advanced solid tumors with microsatellite instability-high/mismatch repair defects Tumor activity and safety
.
Recruited 18-year-old patients with advanced solid tumors who had not received anti-PD-1/PD-L1 treatment and had clear microsatellite instability-high/mismatch repair defects, and received LY3300054 as a single agent (single agent group, n=40) or LY3300054+LY3321367 (pre-treatment combination group, n=20) treatment; PD-1/PD-L1 inhibitor-resistant/refractory patients receive combined treatment (drug-resistant/refractory combination group, n =22)
.
The primary endpoint of the combination group is safety and tolerability
A total of 82 patients were recruited, most of which were colorectal cancer (n=39, 47.
6%) or endometrial cancer (n=14, 17.
1%)
.
In the PD-1/PD-L1 inhibitor resistance/refractory combination group, more than 70% of patients had previous treatment lines ≥3
Colorectal cancer
The occurrence of treatment-related adverse reactions in the three treatment groups
The occurrence of treatment-related adverse reactions in the three treatment groupsTwenty-two (55.
0%) patients in the single-agent group had treatment-related adverse reactions (TRAE), of which 2 patients (5.
0%) were TRAE ≥ grade 3; 13 patients (65.
0%) in the combination group had TRAE, 3 Cases (7.
1%) are TRAE ≥ grade 3
.
TRAE occurred in 6 patients (27.
Twenty-two (55.
Treatment response of patients in the three treatment groups
Treatment response of patients in the three treatment groups13 (32.
5%) and 9 (45.
0%) patients in the single-agent group and PD-1/PD-L1 inhibitor-initial treatment combination group achieved objective remission ; PD-1/PD-L1 inhibitor resistance/ One patient (4.
5%) in the refractory combination group achieved objective remission
.
5%) and 9 (45.
0%) patients in the single-agent group and the PD-1/PD-L1 inhibitor-initial treatment combination group respectively obtained objective remission in the single-agent group and PD-1/PD-L1 inhibitor 13 (32.
5%) and 9 (45.
0%) patients in the initial treatment combination group achieved objective remissions
In summary, LY3300054 single-drug and LY3300054/anti-TIM-3 combination regimen has controllable safety
.
Both treatments showed promising clinical activity in MSI-H/dMMR tumors initially treated with PD-1/PD-L1 inhibitors
Both treatments showed promising clinical activity in MSI-H/dMMR tumors initially treated with PD-1/PD-L1 inhibitors
Original source:
Antoine Hollebecque, et al.
Safety and Antitumor Activity of α-PD -L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High / Mismatch Repair-Deficient Tumors in this message
